Answers are grounded in this paper and cite their sources.
The provision of data sharing statements (DSS) for clinical trials has been made mandatory by different stakeholders. DSS are a device to clarify whether there is intention to share individual participant data (IPD). What is missing is a detailed assessment of whether DSS are providing clear and understandable information about the conditions for data sharing of IPD for secondary use.
No takes yet. Share an insight, caveat, or question.
Ohmann et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: